Consumer medicine information

Curosurf

Poractant alfa

BRAND INFORMATION

Brand name

Curosurf

Active ingredient

Poractant alfa

Schedule

What is in this leaflet

This leaflet answers some common questions about CUROSURF. It does not contain all the available information. It does not take the place of talking to your doctor.

All medicines have risks and benefits. Your doctor has weighed the risks of your baby receiving CUROSURF against the benefits expected from treatment.

If you have any concerns about your baby being given this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What CUROSURF is used for

CUROSURF is used to treat babies suffering from or at risk of a condition called respiratory distress syndrome (RDS). Most babies are born with a substance known as surfactant in their lungs. This substance lines the lungs and stops them from sticking together and so makes normal breathing (respiration) possible. Some babies, however, particularly premature babies, are born without surfactant and this causes RDS.

CUROSURF is a natural surfactant obtained from pigs which works in the same way as human surfactant. It will therefore help your baby to breathe normally until your baby produces their own surfactant.

CUROSURF helps to treat and prevent RDS but cannot be expected to help with other problems which are sometimes associated with premature birth.

CUROSURF is available only with a doctor's prescription.

How CUROSURF is given

CUROSURF is instilled directly into your baby’s trachea or bronchi. CUROSURF is given by a doctor or nurse who is trained and experienced in the care of pre-term babies.

Your baby’s doctor will decide what dose should be given and how long your baby will receive CUROSURF. This depends on your baby’s weight and other factors, such as how premature your baby is.

Each vial of CUROSURF is used once only and the remaining suspension is discarded.

While your baby is being given CUROSURF

The administration of CUROSURF to your baby can affect the ability of your baby’s lungs to take up oxygen. Therefore your baby will be frequently monitored by a nurse or doctor so that oxygen and ventilatory support can be modified as required.

Side Effects

Check with your baby’s doctor as soon as possible if your baby has any problem while being treated with CUROSURF, even if you do not think the problem is connected with the medicine or is not listed in this leaflet.

Like other medicines, CUROSURF can cause some side effects. If they occur, most are likely to be minor and temporary. However, some may be serious and need medical attention.

Ask your doctor to answer any questions you may have.

Side effects may include bradycardia (slow heart rate) and hypotension (low blood pressure). During the administration of CUROSURF with a thin catheter, some mild and transitory adverse events have been seen: bradycardia, apnoea, decreased oxygen saturation, froth at the mouth, coughing, choking and sneezing. Some babies may get other side effects while being treated with CUROSURF. Talk to your doctor if you are worried about CUROSURF causing side effects in your baby.

Do not be alarmed by the possible side effects. Your baby may not experience any of them.

Overdosage

As CUROSURF will be given to your baby in a hospital by a suitably trained doctor, the chance of your baby getting an overdosage is very small. However, should this happen, your baby’s doctor will know what to do.

Storage

CUROSURF should be stored in the pharmacy or on the ward. The suspension should be kept in a refrigerator at 2 ºC to 8 ºC, in the original package for protection from light. Do not shake the suspension.

Unopened vials can be warmed to room temperature up to 24 hours before use. CUROSURF should not be warmed to room temperature and returned to the refrigerator more than once. Vials are for a single use only.

Appearance of CUROSURF

CUROSURF is a white to creamy white suspension which should not be used if there are visible signs of deterioration. It is available in vials of 1.5 or 3 mL which respectively contain 120 mg or 240 mg of the active ingredient poractant alfa.

CUROSURF also contains sodium chloride as an excipient.

Sponsor

Chiesi Australia Pty Ltd
Suite 3, 22 Gillman Street
Hawthorn East Victoria 3123
Australia
Email: [email protected]
Website: www.chiesi.com.au

Australian Registration Numbers:

AUST R 99514 (CUROSURF 120 mg)

AUST R 99515 (CUROSURF 240 mg)

Date of preparation: September 2021

Published by MIMS February 2022

BRAND INFORMATION

Brand name

Curosurf

Active ingredient

Poractant alfa

Schedule

1 Name of Medicine

Poractant alfa.

2 Qualitative and Quantitative Composition

Curosurf (poractant alfa) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal or intrabronchial administration. It is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and about 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). It is suspended in 0.9% sodium chloride solution.
Each millilitre of surfactant mixture contains 80 mg of total phospholipids (including 54 mg of phosphatidylcholine of which 30.5 mg is dipalmitoyl phosphatidylcholine) and 1 mg of protein including 0.3 mg of SP-B.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Suspension for intratracheal administration.
Curosurf is a white to creamy white suspension of poractant alfa.

4 Clinical Particulars

4.1 Therapeutic Indications

Curosurf is indicated for the treatment (rescue) of respiratory distress syndrome (RDS) in premature infants and for prophylactic use in infants at risk of RDS.

4.2 Dose and Method of Administration

For intratracheal administration only.
The clinician administering Curosurf must be experienced in neonatal intensive care, including endotracheal intubation, mechanical ventilation and cardiorespiratory and oxygen monitoring.
Curosurf is administered intratracheally by instillation through a 5 French end-hole catheter and briefly disconnecting the endotracheal tube from the ventilator. Alternatively, Curosurf may be administered through the secondary lumen of a dual lumen endotracheal tube without interrupting mechanical ventilation, or in the delivery room through temporary placement of an ET tube followed by CPAP.
Before administering Curosurf, ensure proper placement and patency of the endotracheal tube. At the discretion of the clinician, the endotracheal tube may be suctioned before administering Curosurf. The infant should be allowed to stabilise before proceeding with dosing.

Rescue treatment.

The initial recommended dose is 2.5 mL/kg birth weight (200 mg/kg). Treatment should commence as soon as possible after diagnosing RDS. Up to two repeat doses of 1.25 mL/kg birth weight (100 mg/kg) each may be administered, at approximately 12 hour intervals, in infants who remain intubated and in whom RDS is considered responsible for their persisting or deteriorating respiratory status. The maximum recommended total dose (sum of the initial and two repeat doses) is 5 mL/kg (400 mg/kg).

Prophylaxis.

A single dose of 100-200 mg/kg should be administered as soon as possible after birth (preferably within 15 minutes). Further doses of 100 mg/kg can be given 6-12 hours after the first dose and then 12 hours later in infants who have persistent signs of RDS and remain ventilator dependent (maximum total dose: 300-400 mg/kg).
Doses may be determined from the Curosurf dosing chart shown in Table 1.

For endotracheal tube instillation using a 5 French end-hole catheter.

Slowly withdraw the entire contents of the vial of Curosurf into a 3 or 5 mL plastic syringe through a large gauge needle (e.g. at least 20 gauge). Attach the precut 8 cm 5 end-hole French catheter to the syringe. Fill the catheter with Curosurf. Discard excess Curosurf through the catheter so that only the total dose to be given remains in the syringe. Immediately before Curosurf administration, the infant's ventilator settings should be changed to a rate of 40 to 60 breaths/minute, inspiratory time 0.5 second, and supplemental oxygen sufficient to maintain SaO₂ > 92%. Keep the infant in a neutral position (head and body in alignment without inclination). Briefly disconnect the endotracheal tube from the ventilator.
Insert the precut 5 French catheter into the endotracheal tube and instill the first aliquot (1.25 mL/kg birth weight) of Curosurf. The infant should be positioned such that either the right or left side is dependent for this aliquot. After the first aliquot is instilled, remove the catheter from the endotracheal tube and manually ventilate the infant with 100% oxygen at a rate of 40-60 breaths/minute for one minute. When the infant is stable, reposition the infant such that the other side is dependent and administer the remaining aliquot using the same procedures. Do not suction airways for 1 hour after surfactant instillation unless signs of significant airway obstruction occur.
After completion of the dosing procedure, resume usual ventilator management and clinical care. In the clinical trials, ventilator management was modified to maintain a PaO₂ of about 55 mmHg, PaCO₂ of 35-45 and pH > 7.3.

For endotracheal instillation using the secondary lumen of a dual lumen endotracheal tube.

Slowly withdraw the entire contents of the vial of Curosurf into a 3 or 5 mL plastic syringe through a large gauge needle (e.g. at least 20 gauge). Do not attach 5 French end-hole catheter. Keep the infant in a neutral position (head and body in alignment without inclination). Administer Curosurf through the proximal end of the secondary lumen of the endotracheal tube as a single dose, given over 1 minute and without interrupting mechanical ventilation.
After completion of this dosing procedure, ventilatory management may require transient increases in FiO₂, ventilatory rate or PIP.

For endotracheal instillation using the intubation surfactant extubation (INSURE) treatment protocol.

There is a third option of administration through an endotracheal tube in the delivery room before mechanical ventilation has been started. In this case a bagging technique is used to distribute the surfactant through the lungs. Extubation to continuous positive airway pressure (CPAP) is an option either in the delivery room or later after admission to the neonatal unit.

Directions for use.

Curosurf should be inspected visually for discolouration prior to administration. The colour of Curosurf is white to creamy white. Curosurf should be stored in a refrigerator at +2 to +8°C. Before use, the vial should be slowly warmed to room temperature and gently turned upside down in order to obtain a uniform suspension. Do not shake.
Unopened, unused vials of Curosurf that have warmed to room temperature can be returned to refrigerated storage within 24 hours for future use. Do not warm to room temperature and return to refrigerated storage more than once. Protect from light. Each single use vial should be entered only once and the vial with any unused material should be discarded after the initial entry.

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in Section 6.1 List of Excipients.
No specific contraindications are yet known.

4.4 Special Warnings and Precautions for Use

Prophylaxis with surfactant should only be performed where adequate delivery room facilities are available and according to the following recommendations:
prophylaxis (within 15 min of birth) should be given to almost all babies under 27 weeks' gestation;
prophylaxis should be considered for babies over 26 weeks but < 30 weeks' gestation if intubation is required in the delivery suite or if the mother has not received prenatal corticosteroids;
when prenatal corticosteroids were administered, surfactant should be administered only if RDS develops;
considering the other risk factors prophylaxis should also be considered in preterm infants when any of the following are present: perinatal asphyxia, maternal diabetes, multiple pregnancies, male sex family history of RDS and caesarean section.
In all other preterm neonates it is recommended that surfactant be administered using early rescue or selective approaches.

Before administration of Curosurf.

Prior to starting the treatment with Curosurf the infant's general conditions should be stabilised. Correction of acidosis, hypotension, anaemia, hypoglycaemia and hypothermia is recommended.

During administration of Curosurf.

In the event of reflux, administration of Curosurf should be stopped and, if necessary, peak inspiratory pressure on the ventilator should be increased until clearing of the endotracheal tube occurs.
Infants whose ventilation becomes markedly impaired during or shortly after dosing may have mucus plugging of the endotracheal tube, particularly if pulmonary secretions were prominent prior to drug administration. Suctioning of infants prior to dosing may lessen the probability of mucus plugs obstructing the endotracheal tube. If endotracheal tube obstruction is suspected, and suctioning is unsuccessful in clearing the obstruction, the endotracheal tube should be replaced immediately.
However, aspiration of tracheal secretions is not recommended for at least 6 hours after administration, with the exception of life threatening conditions.
The administration of exogenous surfactants, including Curosurf, can rapidly affect oxygenation and lung compliance. Therefore infants receiving Curosurf should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.
In the event of occurrence of episodes of bradycardia, hypotension, endotracheal tube blockage and oxygen desaturation (see Section 4.8 Adverse Effects (Undesirable Effects)) administration of Curosurf should be stopped and appropriate measures to normalise heart rate should be considered and undertaken. After stabilisation, the infant can still be treated with appropriate monitoring of vital signs.

After administration of Curosurf.

After administration of Curosurf pulmonary compliance (chest expansion) and oxygenation can improve rapidly, thus requiring prompt adjustment of ventilator settings.
The occurrence of intracranial haemorrhages after Curosurf instillation has been related to reduction in mean arterial blood pressure and early peaks in arterial oxygenation (PaO₂). Avoidance of high PaO₂ peaks by ventilator adjustment immediately after instillation is recommended.
The improvement of alveolar gas exchange can result in a rapid increase of arterial oxygen concentration: therefore, a rapid adjustment of the inspired oxygen concentration should be made to avoid hyperoxia. In order to maintain proper blood oxygenation values, in addition to periodic blood gas analysis, continuous monitoring of transcutaneous PaO₂ or oxygen saturation is also advisable.
Nasal continuous positive airway pressure (nCPAP) can be used to continue the treatment, but only in units equipped to perform this technique.
Infants treated with surfactant should be carefully monitored with respect to signs of infection. At the earliest signs of infection the infant should immediately be given appropriate antibiotic therapy.
In cases of unsatisfactory response to treatment with Curosurf or rapid relapse, it is advisable to consider the possibility of other complications of immaturity such as patent ductus arteriosus or other lung diseases such as pneumonia before the administration of the next dose.
Apnoea and sepsis may occur as consequences of the immaturity of the infants.
Preterm newborns have relatively high incidences of cerebral haemorrhages and cerebral ischemia, reported as periventricular leukomalacia and haemodynamic anomalies such as patent ductus arteriosus and persistence of foetal circulation despite the provision of intensive care. These infants are also at high risk of developing infections such as pneumonia and bacteraemia (or septicaemia). Seizures may also occur in the perinatal period. Preterm babies also commonly develop haematological and electrolyte disorders which may be worsened by severe illness and mechanical ventilation. To complete the picture of complications of prematurity, the following disorders directly related to illness severity and use of mechanical ventilation, necessary for reoxygenation, may occur: pneumothorax, interstitial pulmonary emphysema and pulmonary haemorrhage. Finally, the prolonged use of high concentrations of oxygen and mechanical ventilation are associated with the development of bronchopulmonary dysplasia and retinopathy of prematurity.
Infants born following very prolonged rupture of the membranes (greater than 3 weeks) may have some degree of pulmonary hypoplasia and may not show an optimal response to exogenous surfactant.
Surfactant administration can be expected to reduce the severity of RDS but cannot be expected to eliminate entirely the mortality and morbidity associated with preterm birth, as preterm infants may present other complications associated with their immaturity.
There is no information available on effects of initial doses other than 100 or 200 mg/kg, dosing more frequently than every 12 hours, or administration of Curosurf starting more than 15 hours after diagnosing RDS.
The administration of Curosurf to preterm infants with severe hypotension has not been studied.
When Curosurf was administered with the LISA technique, an increase in frequency of bradycardia, apnoea and reduced oxygen saturation was reported. These events were generally of brief duration, without consequences during administration and easily managed. When these events became serious, the surfactant treatment was stopped and the complications were treated.

Use in the elderly.

No data available.

Paediatric use.

See Section 4.2 Dose and Method of Administration; Section 4.4 Special Warnings and Precautions for Use.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Not known.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
No data available.
No data available.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Clinical trial experience.

Transient adverse effects seen with the administration of Curosurf include bradycardia, hypotension, endotracheal tube blockage and oxygen desaturation.
The rates of common complications of prematurity observed in study 1 are shown in Table 2.

Immunological studies have not demonstrated differences in levels of surfactant/ antisurfactant immune complexes and anti-Curosurf antibodies between patients treated with Curosurf and patients who received control treatment.

Less invasive surfactant administration with a thin catheter (LISA) technique.

In clinical trials, some transient and mild adverse events, without consequences during administration, were more frequent in the LISA groups than in the standard treatment control groups; in particular: oxygen desaturation (57.4% LISA group vs. 26.6% standard group), apnoea (21.8% vs. 12.8%), bradycardia (11.9% vs. 2.8%), froth at the mouth (21.8 vs. 2.8%), coughing (7.9% vs. 0.9%), choking (6.9% vs 1.8%) and sneezing (5% vs. 0). This difference between the two groups could be justified by the less frequent use of sedation in the LISA groups vs. standard of care. The majority of these events were easily managed.
During a spontaneous comparative clinical trial (Study 3) there was an increased incidence of cases of necrotizing enterocolitis requiring surgery (8.4% in the group with LISA method and 3.8% in the group with standard administration-intubation/MV) and focal intestinal perforation requiring surgery (11.2% in the LISA group and 10.6% in the standard group) in the LISA group, with no statistically significant difference between groups. These events could be either complications of prematurity or consequences of treatments used in these preterm babies.

Follow-up evaluations.

Seventy six infants (45 treated with Curosurf) were evaluated at 1 year of age and 73 infants (44 treated with Curosurf) at 2 years of age. Data from follow-up evaluations for weight and length, persistent respiratory symptoms, incidence of cerebral palsy, visual impairment or auditory impairment was similar between treatment groups. In 33 survivors (17 treated and 16 controls) at one year, the mean of the developmental quotient (derived using the Griffiths Mental Developmental Scales) was similar between groups.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

There have been no reports of overdosage following the administration of Curosurf. In the event of accidental overdosage, and only if there are clear clinical effects on the infant's respiration, ventilation or oxygenation, as much of the suspension as possible should be aspirated and the infant should be managed with supportive treatment, with particular attention to fluid and electrolyte balance.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilises the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in respiratory distress syndrome (RDS) characterised by poor lung expansion, inadequate gas exchange and a gradual collapse of the lungs (atelectasis). Curosurf compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants.
Activity.

In vitro.

Curosurf lowers minimum surface tension to ≤ 4 mN/m as measured by the Wilhelmy Balance System.

In vivo.

In several pharmacodynamic studies, Curosurf improved lung compliance, pulmonary gas exchange and survival in premature rabbits.
In pharmacodynamic studies in premature infants, Curosurf treatment produced improved arterial oxygen concentration within 5 minutes of administration, with increases in the ratios of a/A PO₂ and PaO₂/FiO₂. Improved oxygenation allowed reductions in the concentration of inspired oxygen (FiO₂) within 1 hour, and reductions in ventilator settings (peak insufflation pressure and mean airway pressure). Treatment was also associated with increased chest wall movements, improved lung compliance and decreased inspiratory resistance.

Clinical trials.

Activity.

Large international open and controlled clinical trials have documented the therapeutic effects of Curosurf in infants with RDS and preterm infants at risk for RDS. Preterm newborn infants treated with a single dose of Curosurf (1.25-2.5 mL/kg equal to 100-200 mg/kg of phospholipids) showed a rapid and dramatic improvement of oxygenation with reduction of the inhaled oxygen concentration (FiO₂) and increase of PaO₂ and of PaO₂/FiO₂ and a/APO₂ ratios; mortality rate and incidence of major pulmonary complications were shown to be reduced. The administration of a second or third dose of 100 mg/kg further reduced the incidence of pneumothorax and mortality.

Rescue treatment.

The clinical efficacy of Curosurf was demonstrated in one single dose study (study 1) and one multiple dose study (study 2) in the treatment of established neonatal RDS involving approximately 500 infants. Each study was randomised, multicentre and controlled.
In study 1, infants 700-2000 g birth weight with RDS requiring mechanical ventilation and a FiO₂ > 0.60 were enrolled. Curosurf 2.5 mL/kg single dose (200 mg/kg) or control (disconnection from the ventilator and manual ventilation for 2 minutes) was administered after RDS developed and before 15 hours of age. The results from study 1 are shown in Table 3.

In study 2, infants 700-2000 g birth weight with RDS requiring mechanical ventilation and a FiO₂ > 0.60 were enrolled. In this two arm trial, Curosurf was administered after RDS developed and before 15 hours of age as a single dose or as multiple doses. In the single dose arm, infants received Curosurf 2.5 mL/kg (200 mg/kg). In the multiple dose arm, the initial dose of Curosurf was 2.5 mL/kg (200 mg/kg) and subsequent doses of Curosurf were 1.25 mL/kg (100 mg/kg). The results from study 2 are shown in Table 4.

Less invasive surfactant administration with a thin catheter (LISA) technique.

In clinical trials in spontaneously breathing preterm infants Curosurf was administered through the Less Invasive Surfactant Administration (LISA) technique using a thin catheter. Doses were the same as indicated for the other modalities. A small diameter catheter with a mark at 1.5 cm above the tip was placed into the trachea of infants on CPAP. The catheter was placed with this mark at the level of the vocal cord. Continuous spontaneous breathing was ensured with direct visualization of the vocal cords by laryngoscopy. Curosurf was instilled by a single bolus over 0.5 - 3 minutes. After Curosurf instillation, the tube was immediately removed. CPAP treatment was continued during the whole procedure. The surfactant was administered using a suitable semi-rigid thin catheter.
A spontaneous clinical trial (Study 6) has compared the administration of Curosurf with the LISA technique and the standard one (intubation, administration and mechanical ventilation) in two groups of preterm newborns with RDS and gestational age between 23 and 27 weeks (LISA group: n = 108, control group: n = 105). LISA technique was not inferior to the standard one on the primary end-point (survival without bronchopulmonary dysplasia at 36 gestational weeks). The need of mechanical ventilation was significantly reduced with LISA. Preterm infants in the LISA group achieved statistically significant treatment difference for composite secondary endpoints (survival without major complications such as IVH > II, cystic PVL, ROP requiring surgery), compared to infants in mechanical ventilation group. No statistically significant difference in treatment outcomes were found between LISA and control group for other secondary endpoints such as NEC requiring surgery, duration of mechanical ventilation or CPAP or oxygen supplementation (see Table 5).

Prophylaxis.

Three randomised controlled trials (studies 3, 4 and 5) were conducted in which prophylactic use of Curosurf was compared with rescue treatment in premature infants considered to be at risk of RDS (for details, see Table 6). A meta-analysis of the three trials indicated that prophylactic treatment was associated with a reduction in the risk of severe RDS, a reduction in overall mortality and a reduction in chronic lung disease of the newborn (CLDN). Results are summarised in Table 7.

Studies regarding antenatal corticosteroids for accelerating foetal lung maturation for women at risk of preterm birth support the continued use of a single course of antenatal corticosteroids. Treatment with antenatal corticosteroids reduces the risk of neonatal death, respiratory distress syndrome, cerebroventricular haemorrhage, necrotising enterocolitis, infectious morbidity, need for respiratory support and neonatal intensive care unit admission. There is evidence in studies and current clinical practice to suggest benefit across a wide range of gestational ages from 26 to 34 + 6 weeks. Furthermore, there is evidence to suggest benefit in the subgroups of women with premature rupture of membranes and those with hypertension syndromes. A single course of antenatal corticosteroids should be considered routine for preterm delivery.

5.2 Pharmacokinetic Properties

Curosurf is administered directly to the target organ, the lung, where biophysical effects occur at the alveolar surface. No human pharmacokinetic studies to characterise the absorption, biotransformation or excretion of Curosurf have been performed.
No information is available about the metabolic fate of the surfactant associated proteins in Curosurf.

5.3 Preclinical Safety Data

Genotoxicity.

No data available for genotoxicity and reproductive toxicity effects.

Carcinogenicity.

Studies to assess potential carcinogenic effect of Curosurf, or other surfactants have not been conducted. Mutagenicity studies with Curosurf, which included gene mutation assays in bacteria (the Ames test) and Chinese hamster V79 cells, chromosomal aberration assay in Chinese hamster ovarian cells, an assay of unscheduled DNA synthesis in HeLa S3 cells and an in vivo mouse micronucleus test, were negative.

6 Pharmaceutical Particulars

6.1 List of Excipients

The excipients include: sodium chloride, sodium bicarbonate and water for injections.
The pH may be adjusted as required with sodium bicarbonate to a pH of 6.2 (5.5-6.5). Curosurf contains no preservatives.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store Curosurf in a refrigerator at +2 to +8°C.
Unopened vials of Curosurf may be warmed to room temperature for up to 24 hours prior to use. Curosurf should not be warmed to room temperature and returned to the refrigerator more than once.
Store in the original package to protect from light and moisture. Do not shake. Vials are for single use only. After opening the vial, discard the unused portion of the drug.

6.5 Nature and Contents of Container

Curosurf is available in sterile, ready-to-use rubber-stoppered glass type I clear vials containing 1.5 mL (120 mg phospholipids) or 3 mL (240 mg phospholipids) of suspension. One vial per carton.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

CAS number.

129069-19-8.

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only Medicine.

Log in

Consumer medicine information

Curosurf

Poractant alfa

Keep track of your medicines

BRAND INFORMATION